E75.19
Other gangliosidosis
Clinical Classification Guidelines
Inclusion Terms
- GM1 gangliosidosis
- GM3 gangliosidosis
Medical Intelligence & Overview
Other gangliosidosis, classified under ICD-10 code E75.19, refers to a group of rare genetic disorders characterized by the abnormal accumulation of certain fats called gangliosides in the body's cells. These disorders belong to a family known as lysosomal storage diseases, where the body cannot properly break down specific molecules. This buildup causes progressive damage to tissues and organs, particularly affecting the nervous system. Notably, GM1 and GM3 gangliosidoses are specific forms associated with these conditions. Recognizing and understanding these disorders can aid in diagnosis and management, although they often require specialized care.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting enzymes responsible for breaking down gangliosides Autosomal recessive inheritance pattern, meaning both parents carry the gene and pass it on Deficiency of enzymes such as beta-galactosidase in GM1 gangliosidosis or other related enzymes in different types
Key Symptoms: Progressive neurological deterioration, including loss of motor skills Intellectual decline and developmental delays Enlarged organs such as the liver and spleen Facial abnormalities like coarse features Vision and hearing impairments Seizures in some cases Problems with muscle tone, often presenting as weakness or rigidity Growth delays and failure to thrive
Diagnostic & Treatment
Diagnosis Path: Diagnosis is typically based on a combination of clinical evaluation and laboratory tests. These may include measuring enzyme activity levels in blood or tissue samples and genetic testing to identify mutations. Imaging studies, such as MRI, can reveal brain abnormalities associated with the disorder. Early diagnosis is important, although definitive diagnosis often requires specialized biochemical and genetic assessments.
Treatment Protocols: Currently, there is no cure for officially designated other gangliosidosis. Management includes supportive care aimed at alleviating symptoms and improving quality of life. This might involve physical therapy, speech and occupational therapy, and medications to control seizures or other neurological symptoms. In some cases, experimental treatments like enzyme replacement therapy or gene therapy are being researched but are not yet widely available. Multidisciplinary medical teams play a vital role in planning comprehensive care tailored to individual needs.
Clinical Advice & FAQs
Billing Guidance
Is E75.19 a billable ICD-10 code?
Yes, E75.19 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E75.19?
Clinical documentation must specify the nature of Other gangliosidosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference